LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM) Files An 8-K Regulation FD Disclosure
On March 30, 2017, the Company changed its name from “Luckycom Inc.” to “Luckycom Pharmaceuticals Inc.” by filing an Amendment to Articles of Organization to NRS 86.221. It then amended and restated its by-laws to reflect the new corporate name.
This summary is qualified in its entirety by reference to the Certificate of Amendment to Articles of Organization and Amended and Restated By-laws, copies of which were attached as Exhibits 3.1 and 3.2, respectively to the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2017.
In connection with its name change, on April 18, 2017, the Company’s shares of common stock began trading on the OTC Pink under its new ticker symbol “LCOM” and ceased trading under the ticker symbol “LKYM”.
The new CUSIP number for Luckycom Pharmaceuticals Inc.’s shares of common stock is 54960G 109.
The information contained in this Item 7.01 of this Current Report on Form 8-K is being furnished to Item 7.01. This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
About LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM)
Luckycom Pharmaceuticals Inc., formerly Luckycom, Inc. is a shell company. The Company plans to acquire, develop, manufacture and market pharmaceutical medicines in international tenders managed by World Health Organization-Geneva (WHO). The Company has entered into a license agreement with Luckycom Pharma Pte. Ltd. to manufacture, distribute, sell, market and promote the antimalarial medicine Cosunate (artesunate-amodiaquine kit tablets). The Company had not generated any revenue. LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM) Recent Trading Information
LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM) closed its last trading session 00.00 at 1.70 with 500 shares trading hands.
Luckycom Pharmaceuticals Inc., formerly Luckycom, Inc. is a shell company. The Company plans to acquire, develop, manufacture and market pharmaceutical medicines in international tenders managed by World Health Organization-Geneva (WHO). The Company has entered into a license agreement with Luckycom Pharma Pte. Ltd. to manufacture, distribute, sell, market and promote the antimalarial medicine Cosunate (artesunate-amodiaquine kit tablets). The Company had not generated any revenue. LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM) Recent Trading Information
LUCKYCOM PHARMACEUTICALS INC. (OTCMKTS:LCOM) closed its last trading session 00.00 at 1.70 with 500 shares trading hands.